Risk factor
Fair trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Celltrion Pharm Inc. operates as a South Korean pharmaceutical firm, specializing in the creation and distribution of biosimilar medications and over-the-counter (OTC) drugs. Its extensive product portfolio spans a multitude of therapeutic categories, encompassing treatments for conditions related to liver health, inflammation, allergies, respiratory and cardiovascular systems, digestion, hormonal and metabolic disorders, infectious diseases, immune responses, oncology, and general nutrition. The company supplies its pharmaceutical offerings to a diverse client base, including university hospitals and local pharmacies. Established in 1976, Celltrion Pharm Inc. is based in Cheongju, South Korea.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,